• no-js

The mission of the MRC Weatherall Institute of Molecular Medicine (WIMM) is to undertake internationally competitive research into the processes underlying normal cell and molecular biology and to determine the mechanisms by which these processes are perturbed in inherited and acquired human diseases. It is also our mission to translate this research to improve human health. The WIMM is uniquely placed among biomedical institutes throughout the world in its pioneering vision of combining outstanding clinical research with excellent basic science. The WIMM Faculty currently includes an equal mixture of scientists and clinicians working together and in collaboration with the National Institute of Health Research, the NHS and commercial companies with the aim of improving the diagnosis and treatment of human diseases. The major topics of current research include haematology, immunology, stem cell biology, oncology and inherited human genetic diseases. The Institute benefits from strategic support from the MRC.

MRC logo

The Institute values communication with members of the broader scientific community and the general public and with the support of the Medical Research Council (MRC) we have commissioned three short videos to explain our mission.


Five-year research fellowships offered at  new WIMM Centre for Computational Biology

Five-year research fellowships offered at new WIMM Centre for Computational Biology

Posted 02/02/2016

The MRC Weatherall Institute of Molecular Medicine (WIMM) is a world-leading research institution, combining excellence in clinical research with an outstanding track record in basic science. Thanks to a significant investment from the Medical Research Council the Institute will open a new purpose built Centre for Computational Biology in June 2016. The Centre will include up to 40 computational scientists with expertise in bioinformatics, stati ...


Oxford spin-out Orbit Discovery launches peptide-discovery platform

Posted 26/01/2016

Orbit Discovery – a new spinout from the University of Oxford – has raised seed funding to commercialise technology which will help to identify targeted, affordable therapeutic drugs known as peptides. Oxford Sciences Innovation, the £320m investment company established to provide capital and scaling expertise to Oxford spin-outs, is the lead investor in the new company.  Other investors include the Oxford Technology and Innovations EIS Fund led ...

News Archive



Statistical Bioinformatician/Geneticist ref 121832

Posted 15/01/2016

Applications are invited for an enthusiastic Statistical Bioinformatician/Geneticist to join an existing research team (Clinical Genetics Group) led by Professor Andrew Wilkie FRS at the Weatherall Institute of Molecular Medicine (WIMM). This is a fixed-term position funded until 31 January 2019 by the Wellcome Trust, available immediately. This position will allow the successful candidate to participate in several focused research projects and ...

Further Vacancies


From stem cell to specialized cell: but what happens in between?


Stem cells have the remarkable ability to develop into a whole host of highly specialized cell types, but the process by which this happens is extremely transient and therefore enormously challenging to study. However, a new paper from Claus Nerlov’s and Sten Eirik Jacobsen’s labs, published in Nature Cell Biology two weeks ago, is one of the first studies to show that the physical environment within which these elusive cells mature is critical to their development. Bryony Graham explains more.

WIMM Blog Archive